![Peter Lichtlen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Lichtlen
Direktor/Vorstandsmitglied bei
LYSOGENE
Profil
Peter Lichtlen was the founder of Numab Therapeutics AG, founded in 2011, where the title held was Director & Chief Medical Officer from 2011 to 2024.
Current jobs include Independent Non-Executive Director at Lysogene SA since 2018, Director at Numab Innovation AG, Member at FMH Swiss Medical Association, and Member at Swiss Association of Pharmaceutical Professionals, Inc. Former jobs include Director at Sucampo Acquisitions GmbH, Head-Clinical Research & Development at ESBATech, a Novartis Co. GmbH from 2004 to 2009, Senior Medical Officer & VP-European Operations at Sucampo Pharmaceuticals LLC from 2011 to 2014, and Senior Medical Officer & VP-European Operations at Sucampo GmbH from 2011 to 2018.
Education includes a doctorate from the University of Zurich, conferred in 1996.
Aktive Positionen von Peter Lichtlen
| Unternehmen | Position | Beginn |
|---|---|---|
| LYSOGENE | Direktor/Vorstandsmitglied | 01.04.2018 |
Swiss Association of Pharmaceutical Professionals, Inc. | Corporate Officer/Principal | - |
FMH Swiss Medical Association
 FMH Swiss Medical Association Miscellaneous Commercial ServicesCommercial Services Operates an association for doctors and medical practitioners | Corporate Officer/Principal | - |
Numab Innovation AG
 Numab Innovation AG Miscellaneous Commercial ServicesCommercial Services Develops multi specific bio-therapeutics for chronic inflammation and cancer | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Peter Lichtlen
| Unternehmen | Position | Ende |
|---|---|---|
Numab Therapeutics AG
 Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Gründer | 01.07.2024 |
Sucampo GmbH
 Sucampo GmbH Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals and health care products | Corporate Officer/Principal | 01.02.2018 |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services Develops antibody fragment therapeutics | Corporate Officer/Principal | 01.01.2009 |
Sucampo Acquisitions GmbH
 Sucampo Acquisitions GmbH Financial ConglomeratesFinance Provides investment services | Direktor/Vorstandsmitglied | - |
| SUCAMPO PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Peter Lichtlen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
82
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
FMH Swiss Medical Association
FMH Swiss Medical Association Miscellaneous Commercial ServicesCommercial Services Operates an association for doctors and medical practitioners | Commercial Services |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services Develops antibody fragment therapeutics | Commercial Services |
Sucampo Pharmaceuticals LLC
 Sucampo Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures prostone based pharmaceuticals products | Health Technology |
University of Zurich
 University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sucampo GmbH
Sucampo GmbH Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals and health care products | Health Technology |
Swiss Association of Pharmaceutical Professionals, Inc. | |
Numab Therapeutics AG
Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Health Technology |
Lysogene SA
 Lysogene SA BiotechnologyHealth Technology Engages in research and clinical development of gene therapy for neurodegenerative disorders | Health Technology |
Sucampo Acquisitions GmbH
Sucampo Acquisitions GmbH Financial ConglomeratesFinance Provides investment services | Finance |
Numab Innovation AG
Numab Innovation AG Miscellaneous Commercial ServicesCommercial Services Develops multi specific bio-therapeutics for chronic inflammation and cancer | Commercial Services |
